Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence and Prevalence of Chronic and Rare Diseases
4.2.2 Increased Funding in the Healthcare Industry
4.3 Market Restraints
4.3.1 Costly Therapeutic Technology and Machinery
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Market Participant
5.1.1 Biopharmaceutical Business
5.1.2 CMOs and CROs
5.1.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 AstraZeneca PLC
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Celgene Corporation
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Biogen Inc
6.1.7 Amgen Inc
6.1.8 Gilead Sciences Inc
6.1.9 Merck KGaA
6.1.10 CSL Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS